Strategic Advisory Group of Experts on Immunization (SAGE) - November 2012

Background documents

Meeting of the Strategic Advisory Group of Experts on immunization, April 2012 – conclusions and recommendations Weekly Epidemiological Record, 2012, 87, 201–216.

SAGE tracking record of recommendations and action points

Report of the informal pertussis meeting, 26 September 2012

Presentation on pertussis by Thomas Clark delivered at the October 2012 PAHO meeting

Global and Regional Immunization Coverage (1980 – 2011), presentation based on analysis of data provided on the 2012 UNICEF/WHO Joint Reporting Form

Use of new and underutilized vaccines in 2011, presentation based on analysis of data provided on 2012 the UNICEF/WHO Joint Reporting Form

Progress Towards Global Immunization Goals – 2011- Summary presentation of key indicators, presentation based on analysis of data provided on the UNICEF/WHO Joint Reporting Form

Summary report WHO/AFRO. Task Force on Immunization Meeting, Pretoria, South Africa, 21 - 22 June 2012

Report of the XX Meeting of the Technical Advisory Group on Vaccine-Preventable Diseases, Washington DC, 17-19 October 2012

27th Intercountry meeting of national managers of the expanded programme on immunization. Sharm El-Sheikh, Egypt, 16-19 September 2012. Introductory speech by Regional Director

Report of the Regional Committee for the Eastern Mediterranean, October 2012, Fifty-ninth Session resolution EM/RC59/R.1

Report of the 12th meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE), 3-4 October 2012. Copenhagen, Denmark

Report of the 21st Meeting of the Technical Advisory Meeting on Immunization and Vaccine Preventable Diseases in the Western Pacific Region, Manila, 21-23 August 2012

Presentations

Global report including key updates and challenges from regions - J.M. Okwo-Bele

Background documents

Report from the GAVI Alliance GAVI Alliance Board Meeting, 12-13 June 2012, Washington, DC, USA, final minutes

Presentations

Not available.

Background documents

Report of the Global Advisory Committee on Vaccine Safety (GACVS), June 2012

Report of the Immunization Practices Advisory Committee (IPAC), 17-18 April 2012

The report from the most recent IPAC meeting which took place on 2-3 October 2012 is not yet available

The report form the recent ECBS meeting which took place on 15-19 October 2012 is not yet available.

Presentations

Report of the Global Advisory Committee on Vaccine Safety (GACVS) - M. Wharton, Chair of GACVS

Report of the Immunization Practices Advisory Committee (IPAC) - S. Deeks, Chair of IPAC

Report of the Expert Committee on Biological Standardization (ECBS)-E. Griffiths, Chair of ECBS

Report of the Immunization and Vaccine Related Implementation Research Advisory Committee (IVIR-AC)-A. Hinman, Chair of IVIR-AC

Background documents

Polio Endgame Strategy, Legacy & Budget, 2014-2018

Note for the record from 5th Meeting of the SAGE Polio Working Group World Health Organization, Geneva, 3-4 September, 2012

Scientific evidence in support of: Note for the Record: 5th Meeting of the SAGE Working Group, World Health Organization, Geneva, September 3-4, 2012

Letter to Director-General from Serum Institute of India Limited  Report of the Independent Monitoring Board of the Global Polio Eradication Initiative, June 2012

Polio vaccines and polio immunization in the pre-eradication era: WHO position paper

Proposed policy for a global switch from tOPV to BOPV for routine immunization. Annotated background paper to brief SAGE. SAGE polio working group. March 26, 2012

Presentations

Context: Major developments since SAGE April 2012 meeting-B. Aylward, WHO

Polio Endgame Strategy, Legacy & Budget, 2014-2018-A. Freeman, GPEI

Role of IPV in OPV cessation – report of the SAGE Polio Working group-E. Miller, Chair of SAGE Polio Working Group

Accelerating polio emergency eradication efforts - is there a role for expanding the target age groups for bOPV campaigns and/or including IPV in campaigns-H. Jafari, WHO

Background documents

The Monitoring & Evaluation/Accountability Framework for the Global Vaccine Action Plan. Overview

The Monitoring & Evaluation/Accountability Framework for the Global Vaccine Action Plan. The monitoring indicators

Decade of Vaccines commitment guidelines to enable the Global Vaccine Action Plan Implementation - 18 October 2012

Indicator work sheets

The Monitoring & Evaluation/Accountability Framework for the Global Vaccine Action Plan. Resource Tracking

Updating the Global Vaccine Action Plan cost, financing, and impact projections for 2015

SAGE Working Group on the Decade of Vaccines’ Global Vaccine Action Plan. Terms of reference

Draft Global Vaccine Action Plan - Report by the secretariat Sixty-Fifth WHA, A65/22

Resolution on the Global Vaccine Action Plan Sixty-Fifth WHA 26 May 2012 A65/VR/10

Commission on information and accountability for Women’s and children’s health, WHO, 2011

CSOs letter SAGE and WHO concerning the GVAP indicators

Presentation

GVAP key steps to implementation-J.M. Okwo-Bele, WHO

Decade of Vaccine M&E/Accountability Framework-T. Cherian, WHO

GVAP Costing, Financing and impact update and tracking commitments-G. Gandhi, UNICEF

Independent review of progress and reporting to governing bodies-P. Duclos, WHO

Background documents

Expanding the potential impact of Hib vaccines by optimizing the immunization schedules

WHO Position Paper on Haemophilus influenzae type b conjugate vaccines. WER 2006, 81, 445-452

Hib conjugate vaccines: a systematic review of schedule related RCTs - Draft report , 1 October 2012

Systematic review of observational data on effectiveness of Hib vaccines to allow optimization of vaccines schedules. Jackson C, et al. LSHTM, October 2012

Haemophilus influenzae type b conjugate vaccine: Review of observational data on long term vaccine impact to inform recommendations for vaccine schedules- Report Watt JP et al JHU, July 2012

Haemophilus influenzae type b disease in HIV-infected children: a review of the disease epidemiology and effectiveness of Hib conjugate vaccines- Abstract. Vaccine. 2010 Feb 17;28(7):1677-83

Haemophilus influenzae type b vaccine impact in resource-poor settings in Asia and Africa- Abstract Expert Review of Vaccines January 2009, Vol. 8, No. 1, Pages 91-102

Cost-effectiveness of Hib vaccine: Review of the literature-ppt. Griffiths U et al, October 2012

Summary of Previous SAGE Discussions on Hib vaccine

Hib containing vaccine price data - UNICEF Supply Division

Presentations

Overview of Hib burden and progress with vaccine introduction (and questions to SAGE)-P. Fine, London School of Hygiene and Tropical Medicine (LSHTM)

What evidence is available on the current Hib vaccine schedule versus alternative schedules-R. Hajjeh, CDC

Impact and incremental benefits of various Hib vaccines schedules given the disease epidemiology in young children and the actual age at vaccination-C. Sanderson, LSHTM

Expert group conclusions: What are the optimal schedules for Hib vaccines for children living in different epidemiological settings?-J. Abramson, SAGE member

Background documents

Status Report on Progress Towards Measles and Rubella Elimination. SAGE working group on measles and rubella (22 October 2012)

Framework for Verifying Elimination of Measles and Rubella SAGE Working Group on Measles and Rubella. SAGE working group on measles and rubella (18 October 2012)

Measles aerosol vaccine project – report to SAGE. October 2012

Simmons E, et al. Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data.  Lancet Published on line April 24, 2012

This article explains the current WHO/IVB method for estimating measles burden and is followed by an editorial Measles: the burden of preventable deaths authored by Orenstein WA and Hinman AR

Proceedings of the global technical consultation to assess the feasibility of measles eradication, 28–30 July 2010

Presentations

Presentation on progress and challenges to achieving global and regional goals-P. Figueroa, SAGE member and chair of SAGE working group on measles and rubella

Presentation on opportunities and plans to overcome the challenges-P. Strebel, WHO

Presentation on the draft framework for verifying elimination of measles and rubella-N. Crowcroft, SAGE working group on measles and rubella

Aerosol measles vaccination-M. Greco, Chair of the aerosol product development group and A.-M. Henao, WHO

Background documents

Vaccination in acute emergencies: A framework for decision-making, 23 October 2012

Presentations

Introduction and overview of the process; and the three components of the work-H. Rees, Chair of SAGE working group on vaccination in humanitarian emergencies

The decision-making framework-R. Waldman, SAGE working group on vaccination in humanitarian emergencies

Background documents

Global Support for New Vaccine Implementation in Middle-Income Countries. Draft article submitted for publication in Vaccine

Makinen M. et al. New vaccine adoption in lower-middle-income countries. Health Policy and Planning, 2012; 27:ii39-ii49

Excerpt from the November 2010 SAGE meeting report as published in the WER, 2011,(1-2), 14-15 - Lower-middle-income countries: sustainable adoption and financing of new vaccines

Presentations

What is the new context regarding middle-income countries and new vaccine introduction?

Report from Macedonia-S. Manevska, Ministry of Health, The former Yugoslav Republic of Macedonia

EURO report-L. Mosina, WHO EURO

What has been done so far to implement SAGE 2010 recommendations?-S. Schmitt, WHO consultant

What is to be done to respond to country needs and comply with WHA and SAGE recommendations: What WHO and partners are exploring and planning to do?-M. Kaddar, WHO

Developing a strategy to support new vaccines introduction to Middle Income Countries-M. Shirey, UNICEF